• 1. Synthesis of 4-aryl-1,2,3-triazolyl appended natural coumarin-related compounds with antiproliferative and radical scavenging activities and intracellular ROS production modification
  A. Bistrovi?,N. Stipani?ev,T. Opa?ak-Bernardi,M. Juki?,S. Martinez,Lj. Glava?-Obrovac,S. Rai?-Mali? New J. Chem. 2017 41 7531
• 2. Design, synthesis and biological evaluation of esculetin derivatives as anti-tumour agents
  Ping Wang,Yang-Liu Xia,Yang Yu,Jun-Xia Lu,Li-Wei Zou,Lei Feng,Guang-Bo Ge,Ling Yang RSC Adv. 2015 5 53477
• 3. Esculetin inhibits the inflammatory response by inducing heme oxygenase-1 in cocultured macrophages and adipocytes
  Younghwa Kim,Yooheon Park,Seulgi Namkoong,Junsoo Lee Food Funct. 2014 5 2371
• 4. Dihydroxycoumarins as highly selective fluorescent probes for the fast detection of 4-hydroxy-TEMPO in aqueous solution
  K. ?amoj?,M. Zdrowowicz,W. Wiczk,D. Jacewicz,L. Chmurzyński RSC Adv. 2015 5 63807
• 5. Theoretical study on the peroxyl radicals scavenging activity of esculetin and its regeneration in aqueous solution
  Manuel E. Medina,Annia Galano,Juan Raúl Alvarez-Idaboy Phys. Chem. Chem. Phys. 2014 16 1197

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Coumarins and derivatives 6,7-dihydroxycoumarins
• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Coumarins and derivatives Hydroxycoumarins 6,7-dihydroxycoumarins
• Natural Products and Extracts Plant Extracts Plant based Gymnophyton isatidicarpum
• Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Standard Substances

Esculetin (CAS No. 305-01-1): A Comprehensive Overview of Its Chemistry, Biology, and Emerging Therapeutic Applications

Esculetin, chemically known as 7-hydroxycoumarin, is a naturally occurring coumarin derivative with the chemical formula C₉H₆O₃. Its CAS number, CAS No. 305-01-1, uniquely identifies it in the scientific and industrial communities. This compound has garnered significant attention in recent years due to its diverse pharmacological properties and promising applications in pharmaceutical research and drug development.

The structural framework of Esculetin consists of a benzopyranone core, which is a key feature responsible for its biological activity. The presence of hydroxyl and carbonyl functional groups on the aromatic ring enhances its reactivity and interaction with biological targets. These structural attributes have made Esculetin a subject of extensive investigation in various fields, including medicinal chemistry, pharmacology, and natural product research.

One of the most compelling aspects of Esculetin is its wide spectrum of biological activities. Preclinical studies have demonstrated its potential in multiple therapeutic areas. Notably, Esculetin exhibits anti-inflammatory, antioxidant, antimicrobial, and anti-cancer properties. These effects are attributed to its ability to modulate various cellular pathways and interact with specific enzymes and receptors.

In the realm of anti-inflammatory research, Esculetin has been shown to inhibit the production of pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). This mechanism suggests its potential utility in treating chronic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease. Additionally, its antioxidant properties make it a candidate for mitigating oxidative stress-related conditions, including neurodegenerative disorders like Alzheimer's disease.

The antimicrobial activity of Esculetin has also been extensively studied. It has demonstrated efficacy against a range of bacterial and fungal pathogens, making it a promising candidate for developing novel antimicrobial agents. The compound's ability to disrupt bacterial cell membranes and inhibit key metabolic pathways contributes to its broad-spectrum antimicrobial effects.

Emerging evidence from preclinical studies indicates that Esculetin possesses significant anti-cancer potential. Research has shown that it can induce apoptosis (programmed cell death) in various cancer cell lines by activating caspase-dependent pathways. Furthermore, Esculetin has been observed to inhibit the growth of cancer cells by disrupting microtubule formation and inhibiting topoisomerases, which are essential for DNA replication and cell division.

The therapeutic potential of Esculetin is further supported by its ability to cross the blood-brain barrier, allowing it to exert effects within the central nervous system. This property makes it particularly relevant for treating neurological disorders. Recent studies have explored its potential role in neuroprotection against excitotoxicity and oxidative damage, highlighting its promise as a therapeutic agent for conditions such as Parkinson's disease and stroke.

Beyond its direct biological activities, Esculetin also exhibits modulatory effects on several key signaling pathways involved in disease progression. For instance, it has been shown to inhibit the Wnt/β-catenin pathway, which is implicated in various cancers and developmental disorders. Additionally, Esculetin's ability to modulate the Hedgehog signaling pathway suggests its potential utility in treating basal cell carcinoma and other hedgehog-dependent cancers.

The pharmacokinetic profile of Esculetin has been an area of active investigation. Studies have revealed that it exhibits good oral bioavailability and can be metabolized into active derivatives that contribute to its therapeutic effects. Furthermore, its ability to bind to plasma proteins suggests a prolonged circulation time, enhancing its efficacy over time.

The synthetic pathways for producing Esculetin have also been refined in recent years. Researchers have developed efficient methods for isolating Esculetin from natural sources such as angelica sinensis (Dong Quai) and feverfew (Tanacetum parthenium). Additionally, biotechnological approaches have been explored to enhance production yields through microbial fermentation and enzymatic synthesis.

The safety profile of Esculetin has been evaluated through numerous toxicological studies. These studies have indicated that Esculetin is generally well-tolerated at therapeutic doses, with minimal side effects observed in animal models. However, further clinical trials are necessary to fully assess its safety profile in human populations.

The future directions for Esculetin research are multifaceted. Ongoing studies aim to elucidate the precise mechanisms underlying its biological activities and identify novel therapeutic applications. Additionally, efforts are underway to develop novel derivatives of Esculetin with enhanced potency and selectivity for specific disease targets.

In conclusion, Esculetin (CAS No. 305-01-1) is a versatile compound with significant potential in pharmaceutical applications. Its diverse biological activities, coupled with its favorable pharmacokinetic profile, make it an attractive candidate for developing new drugs targeting chronic diseases such as cancer, neurodegenerative disorders, and inflammatory conditions.

• 531-59-9(Herniarin)
• 92-61-5(Scopoletin)
• 486-21-5(Isofraxidin)
• 574-84-5(Fraxetin)
• 486-35-1(Daphnetin)
• 91-64-5(Coumarin)
• 92-48-8(6-Methylcoumarin)
• 487-06-9(Citropten)
• 120-08-1(Scoparone)
• 93-35-6(Umbelliferone)